

# CRIMALDDI

**Co-ordination, Rationalisation, &  
Integration of Antimalarial Drug  
Discovery & Development Initiatives**

STEVE WARD

LSTM

# Backdrop

- **The various European and International antimalarial drug development initiatives are fragmented & uncoordinated**
- **CRIMALDDI aims to**
  - **Maximise potential effectiveness of existing activities**
  - **Potentially shape the agenda for the next decade with Europe as a key player at the centre**

# CRIMALDDI OBJECTIVES

- **Consensus on research priorities**
- **Rolling 5-year action plan to address research priorities**
  - **Quantitative end-points**
  - **Assigned responsibilities**

---

# Reporting




- CRIMALDDI is a 24 month project comprising 2 x 12 month reporting periods
  - The first reporting period covers 1<sup>st</sup> February 2009 to 31<sup>st</sup> January 2010
-

# New partners




- The University of Cape Town and the University of Buea (both partners of ANDI) joined the consortium from the 1<sup>st</sup> September
  - UCT will have a budget to attend meetings
  - The budgets of all other beneficiaries will be reduced by 8% to release to fund ANDI involvement
-

# CRIMALDDI PROCESS




# GMAP FRAMEWORK



- Control:*** Substantial impact with existing tools
- Elimination:*** Reducing to zero all locally-acquired infections  
Complete interruption of transmission
- Research:*** Creation of new tools to meet unmet needs of GMAP

# WHAT BOUNDARIES SHOULD WE SET (1)?



## CRIMALDDI Scope

- Drug discovery projects
- Influence new R&D priorities
- New tools & methods

**WHAT NEEDS TO BE  
DONE?**

**TROPED PHARMA**  
CONSULTING

**WHAT IS BEING WORKED  
ON?**

**TROPED PHARMA**  
CONSULTING

# COMMUNICATIONS PLAN

TROPED PHARMA  
CONSULTING

# Next steps

- **MIM Roundtable (November)**
- **ASTMH EAG Meeting (November)**
- **Website**
- **Journal for final report**
- **Seek opportunities to synergise with ANDI (and other initiatives)**